Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Response-Evaluating human trials: FDA's role.

Shah SK, Kimmelman J, Lyerly AD, Lynch HF, Miller FG, Palacios R, Pardo CA, Zorrilla C.

Science. 2018 Jun 22;360(6395):1308-1309. doi: 10.1126/science.aau0865. Epub 2018 Jun 21. No abstract available.

PMID:
29930129
2.

Bystander risk, social value, and ethics of human research.

Shah SK, Kimmelman J, Lyerly AD, Lynch HF, Miller FG, Palacios R, Pardo CA, Zorrilla C.

Science. 2018 Apr 13;360(6385):158-159. doi: 10.1126/science.aaq0917. Epub 2018 Apr 12. No abstract available.

PMID:
29650663
3.

Pharmacokinetics, Antiviral Activity, and Safety of Rilpivirine in Pregnant Women with HIV-1 Infection: Results of a Phase 3b, Multicenter, Open-Label Study.

Osiyemi O, Yasin S, Zorrilla C, Bicer C, Hillewaert V, Brown K, Crauwels HM.

Infect Dis Ther. 2018 Mar;7(1):147-159. doi: 10.1007/s40121-017-0184-8. Epub 2018 Jan 15.

4.

Zika Virus Infection in Pregnancy: Maternal, Fetal, and Neonatal Considerations.

Zorrilla CD, García García I, García Fragoso L, De La Vega A.

J Infect Dis. 2017 Dec 16;216(suppl_10):S891-S896. doi: 10.1093/infdis/jix448.

PMID:
29267916
5.

Prevalence and correlates of cervical HPV infection in a clinic-based sample of HIV-positive Hispanic women.

Ortiz AP, Tamayo V, Scorsone A, Soto-Salgado M, Febo I, Piovanetti P, Venegas-Ríos HL, Yamamura Y, Zorrilla C.

Papillomavirus Res. 2017 Dec;4:39-44. doi: 10.1016/j.pvr.2017.06.006. Epub 2017 Jun 19.

6.

Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with Men.

Carballo-Diéguez A, Giguere R, Dolezal C, Leu CS, Balán IC, Brown W 3rd, Rael C, Richardson BA, Piper JM, Bekker LG, Chariyalertsak S, Chitwarakorn A, Gonzales P, Holtz TH, Liu A, Mayer KH, Zorrilla CD, Lama JR, McGowan I, Cranston RD; MTN-017 Protocol Team.

AIDS Behav. 2017 Dec;21(12):3336-3345. doi: 10.1007/s10461-017-1969-1.

PMID:
29119473
7.

The View from Puerto Rico - Hurricane Maria and Its Aftermath.

Zorrilla CD.

N Engl J Med. 2017 Nov 9;377(19):1801-1803. doi: 10.1056/NEJMp1713196. Epub 2017 Oct 11. No abstract available.

8.

High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women.

Carballo-Diéguez A, Balán IC, Brown W 3rd, Giguere R, Dolezal C, Leu CS, Marzinke MA, Hendrix CW, Piper JM, Richardson BA, Grossman C, Johnson S, Gomez K, Horn S, Kunjara Na Ayudhya RP, Patterson K, Jacobson C, Bekker LG, Chariyalertsak S, Chitwarakorn A, Gonzales P, Holtz TH, Liu A, Mayer KH, Zorrilla C, Lama J, McGowan I, Cranston RD.

PLoS One. 2017 Jul 27;12(7):e0181607. doi: 10.1371/journal.pone.0181607. eCollection 2017.

9.

MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel.

Cranston RD, Lama JR, Richardson BA, Carballo-Diéguez A, Kunjara Na Ayudhya RP, Liu K, Patterson KB, Leu CS, Galaska B, Jacobson CE, Parikh UM, Marzinke MA, Hendrix CW, Johnson S, Piper JM, Grossman C, Ho KS, Lucas J, Pickett J, Bekker LG, Chariyalertsak S, Chitwarakorn A, Gonzales P, Holtz TH, Liu AY, Mayer KH, Zorrilla C, Schwartz JL, Rooney J, McGowan I; MTN-017 Protocol Team.

Clin Infect Dis. 2017 Mar 1;64(5):614-620. doi: 10.1093/cid/ciw832.

10.

Measuring Knowledge of Cancer Screening and Prevention Strategies in HIV Healthcare Professionals.

Colón-López V, Ortiz AP, Pérez N, Acevedo E, Tamayo V, Zorrilla CD.

P R Health Sci J. 2016 Sep;35(3):147-53.

PMID:
27623140
11.

Pharmacokinetics of once-daily darunavir/ritonavir in HIV-1-infected pregnant women.

Crauwels HM, Kakuda TN, Ryan B, Zorrilla C, Osiyemi OO, Yasin S, Brown K, Verboven P, Hillewaert V, Baugh B.

HIV Med. 2016 Oct;17(9):643-52. doi: 10.1111/hiv.12366. Epub 2016 May 17.

PMID:
27187894
12.

Pharmacokinetics of Total and Unbound Etravirine in HIV-1-Infected Pregnant Women.

Ramgopal M, Osiyemi O, Zorrilla C, Crauwels HM, Ryan R, Brown K, Hillewaert V, Baugh B.

J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):268-274.

PMID:
27159225
13.

HIV and ZIKA in Pregnancy: Parallel Stories and New Challenges.

Zorrilla CD, Mosquera AM, Rabionet S, Rivera-Viñas J.

Obstet Gynecol Int J. 2016;5(6). pii: 180. doi: 10.15406/ogij.2016.05.00180. Epub 2016 Dec 15.

14.

"That's True Love:" Lived Experiences of Puerto Rican Perinatally HIV-Infected Youth within Their Families' Context.

Silva-Suárez G, Bastida E, Rabionet SE, Beck-Sagué C, Febo I, Zorrilla CD.

Int J Environ Res Public Health. 2015 Dec 22;13(1):ijerph13010007. doi: 10.3390/ijerph13010007.

15.

HIV-1-negative female sex workers sustain high cervical IFNɛ, low immune activation, and low expression of HIV-1-required host genes.

Abdulhaqq SA, Zorrilla C, Kang G, Yin X, Tamayo V, Seaton KE, Joseph J, Garced S, Tomaras GD, Linn KA, Foulkes AS, Azzoni L, VerMilyea M, Coutifaris C, Kossenkov AV, Showe L, Kraiselburd EN, Li Q, Montaner LJ.

Mucosal Immunol. 2016 Jul;9(4):1027-38. doi: 10.1038/mi.2015.116. Epub 2015 Nov 11.

16.

Recruitment of Caribbean female commercial sex workers at high risk of HIV infection.

Deschamps MM, Zorrilla CD, Morgan CA, Donastorg Y, Metch B, Madenwald T, Joseph P, Severe K, Garced S, Perez M, Escamilia G, Swann E, Pape JW; HVTN 907 Protocol Team.

Rev Panam Salud Publica. 2013 Aug;34(2):92-8.

17.

Clinical and pharmacogenetic factors affecting neonatal bilirubinemia following atazanavir treatment of mothers during pregnancy.

Eley T, Huang SP, Conradie F, Zorrilla CD, Josipovic D, Botes M, Osiyemi O, Hardy H, Bertz R, McGrath D.

AIDS Res Hum Retroviruses. 2013 Oct;29(10):1287-92. doi: 10.1089/AID.2013.0002. Epub 2013 Jul 19.

18.

Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily.

Zorrilla CD, Wright R, Osiyemi OO, Yasin S, Baugh B, Brown K, Coate B, Verboven P, Mrus J, Falcon R, Kakuda TN.

HIV Med. 2014 Jan;15(1):50-6. doi: 10.1111/hiv.12047. Epub 2013 Jun 3.

19.

Biomedical HIV prevention strategies: state of the art and implications for public health policy in the Caribbean.

Zorrilla CD, Rabionet SE, Mosquera AM, Ramírez de Arellano AB.

P R Health Sci J. 2012 Sep;31(3):170-9.

PMID:
23038893
20.

Levels of felt stigma among a group of people with HIV in Puerto Rico.

Jiméez J, Morales M, Castro E, Puig M, Vélez CN, Santiago L, Zorrilla C.

P R Health Sci J. 2012 Jun;31(2):64-70.

21.

Antenatal screening for Down syndrome with special considerations in the Puerto Rican population.

López-Cepero R, Lynch L, Zorrilla C, Leavitt K, de la Vega A.

P R Health Sci J. 2011 Dec;30(4):206-10. Review.

PMID:
22263303
22.

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.

Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, Wu H, Zorrilla C, Crauwels H, Rimsky LT, Vanveggel S, Boven K; THRIVE study group.

Lancet. 2011 Jul 16;378(9787):229-37. doi: 10.1016/S0140-6736(11)60983-5.

PMID:
21763935
23.

Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women.

Conradie F, Zorrilla C, Josipovic D, Botes M, Osiyemi O, Vandeloise E, Eley T, Child M, Bertz R, Hu W, Wirtz V, McGrath D.

HIV Med. 2011 Oct;12(9):570-9. doi: 10.1111/j.1468-1293.2011.00927.x. Epub 2011 May 16.

24.

Felt Stigma in Injection Drug Users and Sex Workers: Focus Group Research with HIV-Risk Populations in Puerto Rico.

Jiménez J, Puig M, Sala AC, Ramos JC, Castro E, Morales M, Santiago L, Zorrilla C.

Qual Res Psychol. 2011;8(1):26-39. Epub 2011 Mar 16.

25.

Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial.

Currier J, Averitt Bridge D, Hagins D, Zorrilla CD, Feinberg J, Ryan R, Falcon R, Tennenberg A, Mrus J, Squires K; GRACE (Gender, Race, And Clinical Experience) Study Group.

Ann Intern Med. 2010 Sep 21;153(6):349-57. doi: 10.7326/0003-4819-153-6-201009210-00002.

26.

Measuring HIV felt stigma: a culturally adapted scale targeting PLWHA in Puerto Rico.

Jimenez JC, Puig M, Ramos JC, Morales M, Asencio G, Sala AC, Castro E, Velez Santori C, Santiago L, Zorrilla C.

AIDS Care. 2010 Nov;22(11):1314-22. doi: 10.1080/09540121003758481. Review.

27.

Small bimetallic (Pt/Pd) particles by biosynthesis: transmission electron microscopy and quantum mechanical analysis.

Herrera-Becerra R, Zorrilla C, Canizal G, Schabes-Retchkiman PS, Liu HB, Tavera-Davila L, Rosano-Ortega G, Rendon L, Ascencio JA.

J Nanosci Nanotechnol. 2009 Mar;9(3):1935-41.

PMID:
19435062
28.

A multifaceted mentoring model for minority researchers to address HIV health disparities.

Rabionet SE, Santiago LE, Zorrilla CD.

Am J Public Health. 2009 Apr;99 Suppl 1:S65-70. doi: 10.2105/AJPH.2008.153635. Epub 2009 Feb 26.

29.

Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy.

Zorrilla CD, Tamayo-Agrait V.

HIV AIDS (Auckl). 2009;1:41-53. Epub 2009 Dec 8.

30.

Concerns about HIV and sexually transmitted infection among low-risk and high-risk women, Puerto Rico.

Torres R, Hilerio CM, Silva G, Ortiz NY, Zorrilla CD, Santiago LE.

Ethn Dis. 2008 Spring;18(2 Suppl 2):S2-238-41.

PMID:
18646357
31.

Adherence to antiretroviral treatment among pregnant and postpartum HIV-infected women.

Mellins CA, Chu C, Malee K, Allison S, Smith R, Harris L, Higgins A, Zorrilla C, Landesman S, Serchuck L, Larussa P.

AIDS Care. 2008 Sep;20(8):958-68. doi: 10.1080/09540120701767208.

PMID:
18608073
32.

The HVTN protocol 903 vaccine preparedness study: lessons learned in preparation for HIV vaccine efficacy trials.

Djomand G, Metch B, Zorrilla CD, Donastorg Y, Casapia M, Villafana T, Pape J, Figueroa P, Hansen M, Buchbinder S, Beyrer C; 903 Protocol Team.

J Acquir Immune Defic Syndr. 2008 May 1;48(1):82-9. doi: 10.1097/QAI.0b013e31817236ab.

PMID:
18391750
33.

Reduction in the perinatal HIV transmission: the experience at the Maternal Infant Studies Center and Gamma Projects at the University of Puerto Rico School of Medicine.

Zorrilla CD, Tamayo Agrait V, Febo I, Santiago LE, Díaz C, Salabarría I, Pérez E, Hillyer GV.

P R Health Sci J. 2007 Dec;26(4):329-35.

PMID:
18246960
34.

No association between antepartum serologic and genital tract evidence of herpes simplex virus-2 coinfection and perinatal HIV-1 transmission.

Chen KT, Tuomala RE, Chu C, Huang ML, Watts DH, Zorrilla CD, Paul M, Hershow R, Larussa P.

Am J Obstet Gynecol. 2008 Apr;198(4):399.e1-5. doi: 10.1016/j.ajog.2007.10.784. Epub 2008 Feb 21.

PMID:
18177832
35.

Spanish validation of the HIV dementia scale in women.

Wojna V, Skolasky RL, McArthur JC, Maldonado E, Hechavarria R, Mayo R, Selnes O, Ginebra T, de la Torre T, Garcia H, Kraiselburd E, Melendez-Guerrero LM, Zorrilla CD, Nath A.

AIDS Patient Care STDS. 2007 Dec;21(12):930-41.

PMID:
18154490
36.

Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants.

Tremoulet AH, Capparelli EV, Patel P, Acosta EP, Luzuriaga K, Bryson Y, Wara D, Zorrilla C, Holland D, Mirochnick M; Pediatric AIDS Clinical Trials Group.

Antimicrob Agents Chemother. 2007 Dec;51(12):4297-302. Epub 2007 Sep 24.

37.

Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants.

Zorrilla CD, Van Dyke R, Bardeguez A, Acosta EP, Smith B, Hughes MD, Huang S, Watts DH, Heckman B, Jiménez E, McSherry G, Mofenson L.

Antimicrob Agents Chemother. 2007 Jun;51(6):2208-10. Epub 2007 Apr 9.

38.
39.

Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment.

Wojna V, Skolasky RL, Hechavarría R, Mayo R, Selnes O, McArthur JC, Meléndez LM, Maldonado E, Zorrilla CD, García H, Kraiselburd E, Nath A.

J Neurovirol. 2006 Oct;12(5):356-64.

PMID:
17065128
40.

Relationship of pregnancy to human papillomavirus among human immunodeficiency virus-infected women.

Minkoff H, Shen X, Watts DH, Leighty R, Hershow R, Palefsky J, Tuomala R, Neu N, Zorrilla CD, Paul M, Strickler H.

Obstet Gynecol. 2006 Oct;108(4):953-60. Erratum in: Obstet Gynecol. 2007 Jul;110(1):191. Xian, Lin Shen [corrected to Shen, XianLin].

PMID:
17012459
41.

Synthesis and characterization of Mn quantum dots by bioreduction with water hyacinth.

Rosano-Ortega G, Schabes-Retchkiman P, Zorrilla C, Liu HB, Canizal G, Avila-Pérez P, Ascencio JA.

J Nanosci Nanotechnol. 2006 Jan;6(1):151-6.

PMID:
16573087
42.

Mode of delivery and postpartum HIV-1 disease progression: the Women and Infants Transmission Study.

Navas-Nacher EL, Read JS, Leighty RM, Tuomala RE, Zorrilla CD, Landesman S, Rosenblatt H, Hershow RC; Women and Infants Transmission Study Group.

AIDS. 2006 Feb 14;20(3):429-36.

PMID:
16439877
43.

An empowerment intervention for women living with HIV and its adaptation for women with a diagnosis of breast cancer.

Zorrilla CD, Santiago LE, Hilerio C, Estronza G, Falk T.

Ethn Dis. 2005 Autumn;15(4 Suppl 5):S5-128-32.

PMID:
16315392
44.

Posttraumatic stress disorder symptoms and adherence among women living with HIV.

Hilerio CM, Martínez J, Zorrilla CD, Torres R.

Ethn Dis. 2005 Autumn;15(4 Suppl 5):S5-47-50.

PMID:
16315382
45.

Protease inhibitor use in 233 pregnancies.

Morris AB, Dobles AR, Cu-Uvin S, Zorrilla C, Anderson J, Harwell JI, Keller J, Garb J.

J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):30-3.

PMID:
16123678
46.

Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy.

Tuomala RE, Watts DH, Li D, Vajaranant M, Pitt J, Hammill H, Landesman S, Zorrilla C, Thompson B; Women and Infants Transmission Study.

J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):449-73.

PMID:
15764963
47.

Risk factors for in utero and intrapartum transmission of HIV.

Magder LS, Mofenson L, Paul ME, Zorrilla CD, Blattner WA, Tuomala RE, LaRussa P, Landesman S, Rich KC.

J Acquir Immune Defic Syndr. 2005 Jan 1;38(1):87-95.

PMID:
15608531
48.

Effect of hard-drug use on CD4 cell percentage, HIV RNA level, and progression to AIDS-defining class C events among HIV-infected women.

Thorpe LE, Frederick M, Pitt J, Cheng I, Watts DH, Buschur S, Green K, Zorrilla C, Landesman SH, Hershow RC.

J Acquir Immune Defic Syndr. 2004 Nov 1;37(3):1423-30.

PMID:
15483472
49.

Changing trends in clinical AIDS presentations and survival among HIV-1-infected women.

Charurat M, Blattner W, Hershow R, Buck A, Zorrilla CD, Watts DH, Paul M, Landesman S, Adeniyi-Jones S, Tuomala R; Women And Infants Transmission Study.

J Womens Health (Larchmt). 2004 Jul-Aug;13(6):719-30.

PMID:
15333287
50.

Greater adherence to highly active antiretroviral therapy (HAART) between pregnant versus non-pregnant women living with HIV.

Zorrilla CD, Santiago LE, Knubson D, Liberatore K, Estronza G, Colón O, Acevedo M.

Cell Mol Biol (Noisy-le-grand). 2003 Dec;49(8):1187-92.

PMID:
14983985

Supplemental Content

Loading ...
Support Center